Real-World data shows which heart failure drug may be better

NCT ID NCT07376265

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at health records of 1,249 heart failure patients in Portugal to compare two types of medication: sacubitril/valsartan versus older drugs called ACE inhibitors or ARBs. The goal was to see which treatment better prevents heart failure hospitalizations or death from heart problems. Because this was an observational study using existing data, it reflects real-world care but cannot prove cause and effect.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sacubitril/valsartan (a combination drug) compared to ACE inhibitors or ARBs (standard heart failure medications)
What this could lead to
If results are positive, this could support using sacubitril/valsartan as a preferred treatment to reduce heart failure hospitalizations and cardiovascular death.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by unmeasured factors. It also only looked at a specific population in Portugal, so findings may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis

    East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.